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Tumours have a disorganized vascular supply creating foci of low
oxygen tension (Chaplin et al, 1987; Jain, 1988). Hypoxic cells in
these regions are resistant to treatment with radiotherapy, predis-
posing to failure of this modality of treatment. Consequently,
attempts to overcome tumour hypoxia have been made with a
certain degree of success (Overgaard, 1992). Since normal tissues
are usually oxic in comparison with tumours (Vaupel, 1993), this
difference in oxygenation can be exploited for beneficial effect.
One way of achieving this is to use bioreductive drugs which
selectively kill hypoxic cells (Workman and Stratford, 1993;
Adams and Stratford, 1994). These prodrugs require metabolic
activation by enzymes including the one-electron dontor,
NADPH:cytochrome c (P450) reductase (P450R). Endogenous
P450 reductase activity in tumours can be heterogeneous
(Forrester et al, 1994; Forkert et al, 1996). To overcome this, it has
been proposed that the introduction of P450 reductase into
tumours as a therapeutic gene may allow more effective targeting
of the hypoxic areas in tumours by bioreductive drugs (Patterson
et al, 1997).
Tirapazamine (TPZ, SR4233) is a bioreductive drug that is acti-
vated by one-electron reduction to a cytotoxic radical intermediate
prior to further reduction to the non-toxic metabolite SR4317. The
TPZ radical has been shown to elicit selective toxicity towards
hypoxic cells, because under aerobic conditions it is quenched by
molecular oxygen (Brown, 1993). Redox cycling, with the genera-
tion of superoxide radicals is believed to be the cause of under-
lying oxic cytotoxicity (Lloyd et al, 1991). Because of the
selective toxicity of TPZ towards hypoxic cells, preclinical studies
concentrated on combining this bioreductive cytotoxin with either
radiation (Brown and Lemmon, 1990) or other chemotherapeutic
drugs such as cisplatin (Dorie and Brown, 1993). These promising
preclinical studies have resulted in TPZ undergoing clinical evalu-
ation (Rodriguez et al, 1996; Lee et al, 1998) and it is currently in
phase II and III clinical trials as an adjunct to cisplatin-based
chemotherapy or radiation.
Elwell et al (1997) evaluated the biochemical consequences of
chronic aerobic tirapazamine exposure in an effort to determine
the mechanism of oxic toxicity. The A549 wild type (wt) cell line
was grown continuously in incremental concentrations of TPZ
(10, 25, 50 and 100 mM) over a period of approximately 6 months.
Ultimately, the derived lines maintained aerobic resistance to TPZ
without any further selective pressure. The selected cell lineages
were found to have significantly elevated levels of manganese
superoxide dismutase (MnSOD), along with considerably reduced
DT-diaphorase and P450R activity (9.4-, 35.6- and 78.6-fold
respectively). The selected lines were much more resistant to TPZ
under aerobic conditions (using colony survival assays). This oxic
resistance was attributed to both the elevated levels of MnSOD
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MnSOD is an effective radical scavenger it would scavenge any
oxygen radical byproducts generated through redox-cycling, and
so moderate the aerobic toxicity of this drug (Elwell et al, 1997).
As a consequence of the greatly reduced P450R activity, the
selected cells might have been predicted to be more resistant to
TPZ under both aerobic and hypoxic conditions. However, this
was apparently not the case, with the selected lines being only
slightly more resistant under hypoxic conditions (1.5-fold).
Additionally, hypoxic TPZ metabolism remained intact and did
not alter significantly. Considered together, these results suggested
that P450R was involved in the aerobic toxicity of TPZ, but was
not an important factor in the hypoxic activation of this drug. In
contrast, there is another body of evidence showing that P450R
does play a dominant role in the reductive activation, toxicity and
metabolism of TPZ. For example, in a study of six breast cancer
cell lines, it was shown that cellular P450R activity correlated
strongly with both hypoxic metabolism and toxicity of TPZ
(Patterson et al, 1995). Subsequently the breast cancer cell,
MDA231, was transfected with an expression vector containing
human P450R. Stably transfected clones were selected that
showed a 50-fold range in P450R activity and using these clones
the importance of P450R was unambiguously demonstrated for
both hypoxic toxicity and metabolism of TPZ (Patterson et al,
1997). Thus, there are two apparently opposing interpretations
regarding the importance of P450R for TPZ activation and toxicity
under hypoxic conditions. Therefore, in this paper, we have taken
the A549c50 cells that show deficient P450R activity (Elwell et al,
1997) and transfected them with the cDNA encoding P450R.
Stably transfected clones were selected and compared for TPZ
toxicity and metabolism with both the parental A549 cells and the
A549c50 cells derived from them.
MATERIALS AND METHODS
Chemicals
SR4233 was made by a method described by Seng and Ley (1972)
and was synthesized in the Medicinal Chemistry Section of the
School of Pharmacy, Manchester University. NADPH and NADH
were purchased from Boehringer Mannheim (Lewes, UK). Tissue
culture media (Dulbecc’s modified Eagle’s medium, DMEM) was
obtained from Gibco-BRL. Fetal calf serum (FCS) and all other
reagents of analytical grade were purchased from Sigma (Poole,
UK).
Cells and culture
A549 wt and A549c50 cells (Elwell et al, 1997) were grown in
DMEM medium supplemented with 2 mM glutamine and 10%
FCS. The clones were grown in the same media although it also
contained puromycin 2 mg ml–1. All cell lines were maintained in
an exponential growth phase and only clones of five or fewer
passages from their initial selection were used in this project.
Transfection and clonal selection
Details of the expression vector for human P450R cDNA have
been described previously (Patterson et al, 1997). A549c50 cells 
in exponential growth phase were harvested and suspended in
‘Optimix’ buffer (Equibio) to increase cell survival after trans-
fection. Approximately 1 ´ 107 cells were mixed with 20 mg of
pBABE–puro–reductase vector. After 2 min of equilibration, the
sample was electroporated (1500 mF, 290 V) and then immediately
returned to a 15 cm plate containing pre-warmed media. Forty-
eight hours after transfection, puromycin containing media 
(2 mg ml–1) was added to the plate. Eighteen days after transfec-
tion, 48 colonies were picked and seeded into individual wells of a
24-well plate. The cells were maintained under puromycin selec-
tion at all times.
Tumour cell lysates
Cells in exponential growth phase were washed twice with phos-
phate-buffered saline (PBS) and then scraped in ice-cold PBS.
After centrifugation at 100 g for 10 min at 4°C, the PBS was
discarded and the pellet resuspended in 200–500 ml of ice-cold
nuclear buffer A (10 mM HEPES, 1.5 mM magnesium chloride, 
10 mM potassium chloride, 0.05 mM dithiothreitol, pH 7.4). After
standing for 10 min in ice, the suspension was sonicated using an
MSE soniprep 150 (3 ´ 5 s, 23 kHz, oscillation amplitude 
~ 10 mm). Samples were placed on ice between each sonication.
After standing for a further 10 min at 4°C, the sample was
centrifuged at 7800 g for 15 min at 4°C. The resulting lysate was
snap-frozen and then stored at –70°C. The protein concentration
was determined using the Pierce assay with bovine serum albumin
(BSA) as the standard for comparison.
Clonal characterization
Cell lysates made from the A549wt, A549c50 and clonal cell lines,
were assayed for P450R, DT-diaphorase and TPZ metabolism. The
mean from at least three different lysates was taken as the final
result.
P450 reductase activity was determined spectrophotometrically
as the NADPH-dependent reduction of cytochrome c (Patterson 
et al, 1997). Each incubation comprised 400 ml of cytochrome c
(final concentration 50 mM), 100 ml of 10 mM potassium cyanide
(final concentration 1 mM) and 10–300 ml of lysate made up to
0.98 ml with 100 mM phosphate buffer, pH 7.6. The reaction was
equilibrated at 37°C and was initiated by the addition of 20 ml of
10 mM NADPH (final concentration 200 mM). The rate of reduc-
tion of cytochrome c was monitored at 550 nm for 2 min against a
blank without NADPH. Initial rates of reaction were based on an
extinction coefficient of 21 mM–1 cm–1 calculated and expressed as
nmol cytochrome c reduced per min per mg of lysate protein.
DT-diaphorase was determined spectrophotometrically as the
dicoumorol-inhibitable component of the NADPH-dependent
reduction of cytochrome c (Robertson et al, 1994). Activity was
again expressed as nmol cytochrome c reduced per min per mg of
lysate protein.
Metabolism of tirapazamine by cell lysates
Fifty microlitres of lysate was incubated at 37°C under nitrogen
gassing in the presence of excess NADPH (100 ml of 5 mM) and
buffer (0.2 M potassium phosphate pH 7.4). The final volume was
500 ml. After 10 min, 20 ml of 20 mM SR4233 in dimethyl
sulphoxide (DMSO) was added to start the reaction. Forty minutes
later the reaction was stopped by pipetting 200 ml of this reaction
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nitroquinoline) was also added to the tube. The supernatants were
transferred to autosampler vials for analysis by isocratic reverse-
phase high-performance liquid chromatography (HPLC)
(Patterson et al, 1997). The amount of each component was
detected spectrophotometrically at 267 nm. The values were then
corrected for protein content and expressed as nmol SR4317
formed per min per mg protein.
Drug sensitivity
MTT proliferation assay
Details of this assay have been described (Patterson et al, 1995).
Prior to the drug sensitivity studies the seeding density required to
give an optimum optical density following metabolism of 3-(4,5-
dimethylthiazal-2-yl)-2,5-diphenyltetrazolium bromide (MTT),
was determined by growing increasing numbers (1000–10 000
cells per well) of the A549 and derived cell lines in a 96-well plate
for 4 days. At this point the plate was assayed and a seeding
density was chosen that gave an optical density of approximately
0.5 units (Labtech Anthos ht III 96-well plate spectrometer). The
A549c50 cells and transfected clonal lines grew at similar rates
and were seeded at 7000 cells per well. The A549wt cells grew
more rapidly and were seeded at 4000 cells per well.
TPZ was dissolved in DMSO and stored at –70°C (40 mM
stock). A fresh aliquot was used for every experiment. TPZ was
diluted in fresh media to make nine concentrations to be added to
the remaining columns of the 96-well plate.
Cells in exponential growth phase were washed twice in sterile
PBS and then harvested from the flask. After counting, cells were
seeded into 11 out of 12 columns of a 96-well plate. The first
column contained only media. After allowing the cells to adhere
for 1 h, they were exposed to increasing concentrations of TPZ.
The second and third columns contained only cells in media and
were used as controls. Cells were exposed to the drug for 3 h under
aerobic or hypoxic conditions. All hypoxic exposures were
conducted under conditions where residual oxygen in the gas
phase was removed by passage over palladium catalyst. All plas-
tics and media were preincubated in hypoxia for at least 24 h to
remove any residual oxygen, prior to use. After each 3-h exposure,
the drug was removed and fresh media instilled into each well.
Plates were then incubated for 96 h in air at 37°C, prior to deter-
mining cell number using the MTT assay. The concentration of
drug required to reduce the optical density to 50% of that of the
control, IC50, was used as a measure of toxicity of the particular
drug treatment in a given cell line.
Clonogenic survival assay
Cells in exponential growth phase were washed twice in PBS,
harvested, counted and seeded at different densities under hypoxic
conditions into 6-well plates. Seeding density depended on the
severity of the subsequent treatment and ranged from 102 to 107
cells per well. The cells were allowed to adhere for 1 h before they
were exposed to TPZ for 3 h under catalyst-induced hypoxia. The
drug was removed and fresh media added to the wells. The plates
were then incubated at 37°C for between 2 and 4 weeks. For every
individual clonogenic survival determination, three to four dupli-
cate wells were exposed to each concentration of TPZ.
Experiments were repeated four times.
When colonies were seen in the control wells (no drug), the
media was discarded and the cells fixed for 1 min with 70%
alcohol. Bromophenol blue (0.25%) in 20% ethanol was then
added to the wells for 15 min. This was then discarded and the
plate carefully washed in tap water. After drying, the number of
mauve-stained colonies (> 50 cells) in each well were counted.
Statistical analysis
The data was analysed by methods previously described (Patterson
et al, 1995). Statistical significance was tested by the Student’s t-test.
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Table 1 A549 wt, A549c50 and P450R transfected cell lines. Determination
of P450R, DT-diaphorase activity and SR4317 formation (IC50 ± s.d., number
of assays shown in brackets)
Cell line P450R DT-diaphorase SR4317
(nmol cyt c (nmol cyt c formation
min–1 mg–1) min–1 mg–1) (nmol min–1 mg–1
protein)
A549c50 0.76 ± 0.15 (5) 361 ± 67 (5) 2.62 + 0.42 (5)
Clone 10 7.09 ± 1.99 (8) 403 ± 44 (5) 11.92 + 2.31 (5)
A549 wt 22.79 ± 3.84 (7) 1641 ± 325 (7) 15.94 + 2.51 (5)
Clone 46 34.76 ± 1.70 (5) 269 ± 97 (4) 29.11 + 2.69 (5)
Figure 2 Dependence of the IC50 of TPZ in the A549 wt and transfected
clones, on the activity of P450R in the cells. Drug exposures were for 23 h in
air (n n) or hypoxia (l l). Values of IC50 were determined using the MTT assay.
(Error bars = standard errors from at least 3 individual experiments)
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Figure 1 Dependence on the expression of P450R, measured as nmol 
cyt c reduced per min per mg cell lysate protein, in the A549 wt, A549 c50
and transfected clones, for hypoxic metabolism of TPZ to SR 4317. (Error
bars = standard deviations)
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P450 reductase (P450R) activity was measured in A549 wt,
A549c50, and two isolated clonal cell lines (clone 10 and clone
46) that displayed P450R activities above and below that of the
parental A549 cell line. The results are displayed in Table 1.
Elevation in P450R activity above the A549c50 cell line ranged
from 9.3-fold in clone 10 to 45.7 times in the highest expressing
clone (clone 46). The P450R activity for the A549wt cell line was
found to be midway between these two values (30 times greater
than the A549c50 cell line).
The A549c50 cell line had fivefold lower DT-diaphorase
activity than the A549wt cell line (Elwell et al, 1997). We have
confirmed this observation (Table 1) and to ensure that the trans-
fection of P450R did not modify the activity of this enzyme,
potentially important in the activation of TPZ, we have also
carried out measurements in the clonal lines 10 and 46. Values of
activity are given in Table 1 and indicate that both of the clones
had similar DT-diaphorase activity to the A549c50 cell line.
To determine whether overexpression of P450R conferred
elevated metabolism of TPZ in the clonal lines, the rate at which
cell lysates reduced TPZ to its two-electron reduction product
(SR4317) under hypoxic condition was determined. Data plotted
in Figure 1 shows that there is a good correlation between P450R
activity and SR4317 formation and that this was highly significant
(slope = 1.69 ± 0.22; P = 0.017).
The cytotoxicity of TPZ under aerobic and hypoxic conditions
was determined using the MTT proliferation assay. Values of IC50
and a summary of these results is tabulated in Table 2 and
displayed graphically in Figure 2. There was a clear relationship
between P450R activity of cell lysate and TPZ cytotoxicity 
under both aerobic and hypoxic conditions. In hypoxia, slope 
= –1.66 ± 0.29; P = 0.0023. The greatest toxicity (lowest IC50),
occurred in clone 46, which had the highest P450R activity, whilst
the value for the A549wt cell line fell between that of the two
clones. The results for the clonogenic survival of the different cell
types exposed to tirapazamine under hypoxic conditions are given
in Figure 3. The control plating efficiency for the cell lines
was:A549wt, 22.50% ± 8.06 (n = 4); A549c50, 3.06% ± 2.00 
(n = 4); Clone 46, 3.74% ± 2.14 (n = 4). From the data it can be
seen that the transfection of P450R into the A549c50 cell line
restores the hypoxic sensitivity of clone 46 to tirapazamine. These
data are therefore consistent with the results obtained using the
MTT proliferation assay.
DISCUSSION
We have successfully introduced an expression cassette encoding
the full length cDNA for human P450R into a derivative of the
A549 NSCLC cell line (A549c50), which had low endogenous
levels of this flavoenzyme. Two representative clones were
selected which had P450R activity above and below that of the
parental cell line. Under both aerobic and hypoxic conditions,
P450R was found to be strongly implicated in the activation and
subsequent toxicity of TPZ. This was consistent with the previous
findings in both a panel of breast cancer cell lines (Patterson et al,
1995) and P450R over-expressing MDA231 clones (Patterson et
al, 1997).
By restoring P450R activity to the A549c50 cell line, the sensi-
tivity to tirapazamine, as determined by the MTT proliferation
assay, increased under both aerobic and hypoxic conditions
(Figure 2). To further evaluate the role of P450R in the hypoxic
sensitivity to tirapazamine, clonogenic survival assays were
performed. Clone 46, which had a P450R activity slightly above
that of the parental line, was compared to the latter and to the
A549c50 cell line from which it was derived. We found that the
hypoxic sensitivity was fully restored by the introduction of
P450R into the resistant A549c50 cell line (Figure 3).
It is of note that clone 46 has moderately greater P450R activity
compared to the A549 wt cell line (35 v 23 nmol cyt c reduced
min–1 mg–1), and so might be anticipated to exhibit hypersensitivity
to TPZ. Yet a number of other metabolic differences existed
between clone 46 and the A549 wt cell line. These included
reduced DT-diaphorase activity (Table 1) and elevated MnSOD
levels which were found in the parental A549c50 cell line. Riley et
al (1993) have shown that murine DTD is not significantly
involved in the anaerobic microsomal reduction of TPZ. Further,
Patterson et al (1994) did not observe a relationship between DTD
activity and either aerobic or hypoxic TPZ sensitivity in a panel of
18 human lung and breast carcinoma cell lines. The apparent
inability of the 5000-fold range in DTD activity to influence the
12-fold range in TPZ sensitivity in vitro, together with the lack of
NAD(P)H-dependent SR4317 formation under aerobic conditions,
strongly argues against a significant role for human DTD in the
metabolism and cytotoxicity of TPZ. This is confirmed in studies
by Plumb and Workman (1994) who used two colon carcinoma
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Table 2 Response to TPZ under aerobic and hypoxic conditions (IC50 ± s.d.,
number of exposures shown in brackets
Cell line 3-hour 3-hour Differential
aerobic hypoxic toxicity
A549c50 1785 ± 528 (4) 63.0 ± 19.8 (6) 28.3
Clone 10 1185 ± 188 (3) 33.0 ± 10.3 (5) 35.9
A549 wt 323 ± 83 (5) 11.0 ± 7.2 (6) 29.4
Clone 46 148 ± 27 (4) 7.4 ± 1.0 (4) 20.0
TPZ concentration (mm)
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Figure 3 Cells exposed to TPZ for 3 hours under hypoxic conditions.
Dependence of surviving fraction, as assayed using clonogenic survival, on
TPZ concentration. A459 wt (n n): A549c50 (l l); clone 46 (∆ ). (Error bars =
standard deviations)cell lines, HT29 and BE which have large differences in DT
diaphorase activity but essentially similar sensitivities to TPZ. In
contrast the difference in MnSOD levels may explain the relative
resistance of this clone in air, since the excess MnSOD would
scavenge the superoxide radicals so reducing the sensitivity to
TPZ. Also, since many changes were induced by chronic TPZ
exposure, it would not be unreasonable to suggest that other
unknown differences also exist, that might contribute to the rela-
tive aerobic resistance of clone 46.
It is thought that the mechanisms of aerobic and hypoxic cyto-
toxicity are distinct (Brown, 1993). Under hypoxic conditions a
free radical intermediate is generated by one electron reduction of
the parent compound (Lloyd et al, 1991). This cytotoxic radical is
believed to abstract a hydrogen atom from DNA and produce
multiple single and double strand-breaks which ultimately lead to
chromosomal defects. Under aerobic conditions, the unstable tira-
pazamine radical is rapidly back-oxidized to the parent compound,
with the subsequent generation of superoxide radicals, which are
in themselves moderately cytotoxic (Lloyd et al, 1991). Thus,
although the mechanisms of toxicity are distinct, P450R is impli-
cated in both the aerobic and hypoxic activation of tirapazamine.
The current results, together with those of Patterson et al (1997),
establish unequivocally that transfection of the cDNA for P450
reductase into human tumour cells increases both the aerobic and
hypoxic sensitivity to tirapazamine. The data published by Elwell
et al (1997) showed that the derived cell lines with reduced P450R
activity were much more resistant to TPZ under aerobic conditions
but were only minimally less sensitive under hypoxic conditions.
This selective loss of aerobic but not hypoxic toxicity reported by
Elwell et al (1997) is difficult to reconcile considering the known
redox properties of P450R. Since this flavoenzyme exists as an air-
stable semiquinone radical, probably FAD-FMNH (Vermilion and
Coon, 1978; Yasukochi et al, 1979), it will donate electrons to any
appropiate artificial electron acceptor (i.e. TPZ). The presence or
absence of molecular oxygen will not markedly influence its
catalytic properties. The hypoxia selectivity is a distinct property
of the TPZ radical species and its interrelationship with the oxygen
couple. By implication this is independent of its mechanism of
activation.
SR4317 formation and colony survival results obtained here
differ from those obtained by Elwell et al (1997) with the same cell
lines. Elwell et al (1997) did not find a significant difference in
either SR4317 formation or hypoxic sensitivity to tirapazamine,
between the A549wt and A549c50 cell lines. It is possible that
these discrepancies may reflect the different techniques used. To
determine SR4317 formation, Elwell et al (1997) used whole cells
whilst in this report metabolism was determined using S-9 fractions
derived from cell lysates in the presence of excess amounts of
NADPH as a cofactor. It is possible that the availability of NADPH
as a cofactor in drug activation may well be influenced by
prevailing metabolic conditions, forming a coupled interactive
system and therefore constituting a control point in drug activation.
The data obtained based on the methodology used by Elwell and
colleagues (Elwell et al, 1997) indicated that SR4317 formation
rate was essentially identical between the A549wt and A549c50
cells despite the very dramatic differences in P450R activity. On the
contrary the data reported here clearly establishes that the differ-
ences seen in P450R activity are also reflected in the relative ampli-
tude of SR4317 formation rates. This is consistent with the well
documented contention of a major role played by P450R in TPZ
metabolism under hypoxia. Further, in our experiments, the colony
survival results agree with the MTT proliferation assay results and
both sets of data are also compatible with the hypothesis that
P450R is involved with the hypoxic activation of TPZ.
The contribution of other intracellular reductases in the activa-
tion of TPZ has been examined and is still unclear (Patterson et al,
1998). Both P450R and the cytochrome P450 family are capable
of metabolizing TPZ. The contention that P450R may not play a
dominant role in TPZ cytotoxicity was put forward by Evans et al
(1998) who suggested that only radicals generated in the nucleus
would contribute to intranuclear DNA damage. Since P450R was
not detected in nuclear fractions, consistent with its microsomal
localization, it was eliminated as the candidate intranuclear
enzyme responsible for TPZ metabolism. Yet, since the reticular
membrane is closely associated with the nuclear membrane and
the TPZ radical is thought to be sufficiently stable to diffuse over
significant distances (Laderoute et al, 1988), it seems reasonable
that cytotoxic radicals generated by reduction of TPZ in the
reticular membrane may be able to diffuse into the nucleus.
Irrespective of the site of radical generation, our results show that
elevated expression of P450R makes human tumour cells more
sensitive to TPZ under both aerobic and hypoxic conditions.
Hypoxia can be considered a tumour phenomenon since the
oxygen tension is often low compared to that of the adjacent
normal tissues. Bioreductive drugs take advantage of this physio-
logical difference by eliciting selective toxicity towards hypoxic
cells. We have shown that transfection of the cDNA for P450R
into a NSCLC cell line enhances the aerobic and hypoxic cyto-
toxicity of TPZ. This is in direct agreement with previous work
published by Patterson et al (1997) using a breast cancer cell line.
In the same study, high P450R expressing clones were also more
sensitive to the 2-nitroimidazole, RSU1069, under hypoxic condi-
tions. Using identical clones, a similar result was obtained with
indolequinone EO9 and two related analogues (Saunders et al,
1996). In summary, we have shown that transfection of the full-
length cDNA for P450R into both breast cancer and non-small-cell
lung cancer cell lines increases the hypoxic sensitivity to TPZ and
also a wide range of other bioreductive drugs.
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